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Semaphorins (Semas) are a large family of traditional axon guidance molecules. Through interactions with 
their receptors, Plexins and Neuropilins, Semas play critical roles in a continuously growing list of diverse 
biological systems. In this review, we focus on their function in regulating vascular development. In 
addition, over the past few years a number of findings have shown the crucial role that Semas and their 
receptors play in the regulation of cancer progression and tumour angiogenesis. In particular, Semas control 
tumour progression by directly influencing the behavior of cancer cells or, indirectly, by modulating 
angiogenesis and the function of other cell types in the tumor microenvironment (i.e., inflammatory cells and 
fibroblasts). Some Semas can activate or inhibit tumor progression and angiogenesis, while others may have 
the opposite effect depending on specific post-translational modifications. Here we will also discuss the 
diverse biological effects of Semas and their receptor complexes on cancer progression as well as their 




Semaphorins and their receptors: 
The Semas are a large family of secreted and membrane-bound proteins originally identified as axon 
guidance cues and later shown to be key regulators in many biological processes including vascular 
development and cancer.  Based on structural similarities, the Semas are grouped into 8 classes, all of which 
carry a  N-terminal Sema domain.  Semas signal via two major receptor families, Plexins and Neuropilins 
(Nrps or Npns). Membrane-bound Semas bind and signal directly through Plexins whereas most of the class 
3 secreted Semas (Sema3A-3G) are known to bind to a holoreceptor complex consisting of Nrps as the 
ligand binding subunit and Plexins as the signal transducing subunit [1-3]. The exception to this rule is 
Sema3E, which binds its receptor Plexin-D1 directly and independently of the Nrps [4].  There are four 
groups of Plexins (A, B, C, and D) that have been identified so far, and similar to Semas, all Plexins have 
Sema domains in their extracellular region. In addition, Plexins have Met-related sequences (MRS) and 
glycine/proline-rich motifs in the extracellular region. The intracellular domains of Plexins do not have 
obvious enzymatic activity, but most of them have weak sequence similarity to GTPase activating proteins 
(GAPs) and exhibit GAP activity towards the small GTPase R-Ras [5].  Moreover, their intracellular regions 
all contain two highly conserved intracellular domains known together as the SEX-plexin domain.  Recent 
structural work has revealed that binding of each homodimer arrangement of Sema and Plexin forms a 
heterodimer complex that then elicits a conformational change in the complex.   This structural alteration 
transmits signals to the intracellular domain of Plexins [6]. In contrast to Plexins, Nrps (Nrp1 and Nrp2) have 
a very short cytoplasmic domain with a PDZ-binding motif at the C-terminal. The extracellular domains of 
Nrps contain two complement-binding domains (a1 and a2), two coagulation factor V/VIII homology 
domains (b1 and b2), and a MAM domain (c).  Importantly, besides binding to Sema3s, Nrps also bind to a 
structurally different family of ligands, the VEGF family, and serve as their co-receptors [7]. Although the a1 
domain is only required for Sema3 binding, the b1 domain is required for both Sema3 and VEGF binding 
[8].	  Thus,	  determining the precise contributions of Sema3s and Nrps is complex because Nrps also control 




Semaphorins in developmental angiogenesis 
It was initially suggested that Sema3s compete with VEGF to bind to Nrp1 and therefore Sema3s inhibit 
VEGF-induced angiogenesis.  Some in vitro data also suggest that Sema3s negatively regulate endothelial 
migration, for example Sema3A inhibits endothelial cell migration and survival [9,	  10]. However, in vivo 
studies using knockout mice thus far show very little evidence for the role of Sema3s in developmental 
angiogenesis except in the case of Sema3E (see below). In the case of Sema3A, no obvious developmental 
vascular patterning defect were found in mice selectively lacking Sema3-Nrp1 signaling	  [11] or mice lacking 
Sema3A [12].  In addition, Sema3B-, Sema3F-, and Sema3G-null mice are also viable and fertile with no 
overt vascular defects. Sema3C null mice die perinatally from cardiac defect [13]. Therefore, most of the 
Sema3s are perhaps not required for the early stages of developmental angiogenesis, but rather play a role 
during vessel remodeling and pathological angiogenesis (see other sections of the review).  For example, 
Sema3A is expressed in endothelial cells and in an autocrine manner regulates endothelial cell migration and 
vessel remodeling by inhibiting integrin function [14]. However, the molecular mechanisms by which 
Sema3A regulates integrins are not fully understood.  Moreover, recent work demonstrated that genetic 
deletion of Sema3A in mice results in severe renal vascular patterning defects, further support the role of 
Sema3A in angiogenic remodeling [15] Most Sema3s have an inhibitory function on in vitro endothelial cell 
migration assays, but whether this inhibitory effect is due to competitive Nrp binding and therefore the 
inhibition of VEGF signaling as was originally proposed is still unclear (see more discussion in the Nrp 
section).  
 
The most obvious Sema3 member to play a key role in regulating developmental angiogenesis is Sema3E 
and its receptor Plexin-D1. Unlike other class 3 secreted Semas that require Nrps as an obligatory ligand-
binding subunit in the Plexin/Nrp holoreceptor, Sema3E can bind and signal through Plexin-D1 independent 
of Nrps. As a novel ligand-receptor pair, Sema3E-Plexin-D1, plays a critical role in shaping the vascular 
network during development [4].  During intersomitic vessel formation, Sema3E is expressed in the caudal 
region of each developing somite, whereas Plexin-D1 is expressed in the intersomitic blood vessels adjacent 
to the somite boundary in the rostral region of each somite.  Sema3E acts as a repulsive cue to restrict vessel 
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growth and branching in the intersomitic space. As a result, both Sema3E and Plexin-D1 knockout mice 
exhibit severe intersomitic vessel patterning defects. Specifically, the intersomitic vessels are no longer 
excluded from the normal Sema3E-expressing caudal region of the somite and extended ectopically 
throughout the somites, resulting in exuberant growth and a loss of the normal segmented pattern [4,	  16].  
Plexin-D1 morphant zebrafish exhibit similar defects in intersomitic vessel patterning [17].  In addition to its 
function in intersomitic vessel patterning, recent work also demonstrates that Sema3E plays a role in the 
initial formation of the dorsal aorta.  Sema3E secreted from the notochord and lateral plate mesoderm are 
required for the formation of avascular regions that coordinate to sculpt the mouse dorsal aorta.  In Sema3E 
knockout embryos, a branched aortic plexus develops abnormally with a markedly narrowed avascular 
midline [18].  Therefore, the repulsive gradient generated by Sema3E in the mouse somite as well as the 
notochord and lateral plate mesoderm determines the proper patterning of Plexin-D1-expressing intersomitic 
vessels and the dorsal aorta, respectively.  
 
The molecular mechanism underlying Sema3E-Plexin-D1 signaling in vascular patterning has been linked to 
the well known VEGF pathway by several studies in both mouse and zebrafish [19] [20] [21] [22].  In the 
developing retinal vasculature, Sema3E is expressed uniformly by retinal ganglion cells (RGCs), but Plexin-
D1 is selectively expressed in endothelial cells at the front of actively sprouting blood vessels and VEGF is 
necessary and sufficient for the dynamic expression of Plexin-D1 [19] [20]. In turn, Sema3E-Plexin-D1 
signaling then negatively regulates VEGF-induced Dll4-Notch signaling and subsequently changes the 
tip/stalk cell ratio.  As a result, a lack of Sema3E or Plexin-D1 in mice leads to a disruption of vascular 
patterning in retinal vasculature, generating an uneven growing front and a less-branched network [19]. It has 
been suggested that VEGF-Notch feedback and dynamic tip and stalk cell position-shuffling promotes 
reiterative sprouting and branching and thus robust network formation during angiogenesis [23].  Because 
Sema3E-Plexin-D1 signaling negatively regulates VEGF signaling, it will be interesting to know whether 
Sema3E-Plexin-D1 is actively involved in regulating the timing of the tip/stalk cell switching during 




In zebrafish, the cross-talk between VEGF and Sema3E-Plexin-D1 signaling are found to be mediated by 
soluble Flt1 (sFlt1). Plexin-D1 antagonizes VEGF signaling by promoting the expression of sFlt1, a 
Flk1/VEGFR2-decoy, in endothelial cells, and the loss of Plexin-D1 induces the sprouting of ectopic 
segmental arteries [17] [21].  Therefore, the interplay between Plexin-D1 and VEGFR seems to be 
evolutionarily conserved during vascular development.  It will be interesting to determine whether Plexin-D1 
functions to regulate VEGFR signaling via enhancing sFlt1 expression in mammalian vascular development.  
In addition, since the elimination of Sema3E in zebrafish does not lead to the phenotype seen in mammals 
[24], it will be interesting to identify the ligand(s) associate with Plexin-D1 in fish.  This result clearly 
demonstrates the existence of both evolutional similarity and difference across species.   
 
 Finally, cross-talk between Sema3E-Plexin-D1 and VEGF has also been shown during pathological 
angiogenesis, which is achieved through the activation of the small GTPase RhoJ. In contrast to the VEGF-
induced activation of Cdc42, which plays a crucial role in filopodia protrusion, Sema3E-induced activation 
of RhoJ mediates endothelial filopodia retraction[20].   
 
It should be mentioned that like in the nervous system, Semas can also function as an attractant in some 
cases.  Although so far most of the data show that Semas inhibit endothelial cell migration, some Semas also 
exhibit pro-angiogenesis function. For example, Sema4D-Plexin-B1 signaling promotes endothelial cell 
migration and tube formation [25,	  26]. Moreover, Sema3C has been shown to increase endothelial migration 
and proliferation in renal glomeruli [27].  
 
Neuropilins in developmental angiogenesis 
The role of Nrps in angiogenesis is complicated by the fact that they bind to both Sema3s and VEGF 
families.  Large amounts of in vitro work trying to elucidate the precise function of Nrps in angiogenesis 
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have generated controversial results and the interpretations of these studies make Nrps even more 
mysterious.  For example, when Nrp1 was originally identified as a receptor for VEGF, the authors showed 
that in heterologous cells, Nrp1 and VEGFR2 were capable of forming a complex that could be 
immunoprecipitated only in the presence of VEGF-165, which binds both receptors. Therefore, they 
proposed that VEGF forms a bridge between the two proteins [28]. It has been shown that when stimulated 
with VEGF, endothelial cells only expressing Nrp1 do not migrate, endothelial cells only expressing 
VEGFR2 migrate, whereas those expressing both Nrp1 and VEGFR2 showed enhanced chemotaxis 
compared with endothelial cells expressing VEGFR2 alone [10]	  [29].  Nrp1/VEGFR2 complex formation has 
been shown to require the PDZ-binding domain of Npn-1 [30].  A recent in vitro loss of function study 
showed that when VEGF binding to Npn1 was abolished, the Nrp1/VEGFR2 association was disrupted [31]. 
However, it has not been shown definitively whether Nrp1 in association with VEGFR2 has a higher affinity 
for VEGF than VEGFR2 alone.  It has also not been demonstrated whether Nrp1 increases the intrinsic 
catalytic activity of the VEGFR2 kinase domain.  Moreover, there is disagreement in the literature as to 
whether the association of Nrp1 and VEGFR2 is VEGF-dependent, with some groups reporting VEGF-
induced Nrp1 association with VEGFR2 [28,	  32], while other studies were able to co-immunoprecipitate 
VEGFR2 and Nrp1 in the absence of VEGF [33]	  [34]. These disagreements in literature could be due to 
different in vitro settings and overexpression systems.  In vivo loss of function experiments are required to 
address the precise role of Nrps in developmental angiogenesis.  
 
Some in vitro studies have also proposed that VEGF binding to Nrp1 can lead to signaling through Nrp1 
itself. For example, one study used a chimeric receptor consisting of the extracellular portion of the EGF 
receptor and the intracellular domain of Nrp1 and found that activation of this receptor with EGF was able to 
induce cell migration that was not present when cells were transfected with wild-type Nrp1 or wild-type 
EGFR [35]. Although Nrp1 has a very short intracellular domain (ICD) with little homology to known 
signaling domains, the very C-terminal of the ICD contains a PDZ-binding motif. A yeast two-hybrid screen 
was used to screen for proteins that interact with the ICD, and a protein called GIPC was identified and 
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shown to bind to the PDZ binding motif [36].  However, GIPC knockout mice have a fairly mild vascular 
phenotype compared to the Nrp1 null [37]. A separate study found that VEGF-induced migration of 
HUVECs was reduced in cells that were infected with an adenovirus vector encoding Nrp1 lacking its C-
terminus	  [38]. Yet, mice lacking the Nrp1 ICD domain were shown to have none of the embryonic vascular 
or cardiac defects of Nrp1 nulls [39]. 
 
Several mouse models have been generated that allow us to delineate Nrp1 function in angiogenesis in vivo.  
First, consistent with its dual binding to Sema3 and VEGF, Npn-1 null mice die very early during 
embryogenesis and exhibit both neural and vascular defects [40,	  41]. Second, mice lacking Nrp1 specifically 
in endothelial cells demonstrated that Nrp1 is cell autonomously required for developmental angiogenesis in 
endothelial cells [11]. When the conditional Nrp mice were generated and crossed with an endothelial-
specific Cre line (Tie2-Cre), the mutant embryos exhibit severe vascular defects including large and 
abnormal clumps of vascular aggregates. In contrast, neuronal-Cre-driven Nrp1 mutants (Npn1flox/flox; Nestin-
Cre) have none of the vascular defects of the endothelial-Cre-driven mutants, but do recapitulate the 
defasciculation defects seen in the Nrp1 null.  Therefore, Nrp protein is absolutely essential in endothelial 
cells for developmental angiogenesis.  Third, to further address which ligands are responsible for Nrp1’s 
anti-angiogenesis function in endothelial cells, another mouse line, Npn1Sema- mice carrying a mutation that 
specifically abolishes Sema3 binding but not VEGF binding were generated [11].  Like the neuronal-specific 
knockout, the Npn1Sema- mice have a variety of neural developmental defects, but surprisingly, did not exhibit 
any vascular phenotypes.  This in vivo result demonstrated that Sema3A-Npn1 interaction is critical for 
nervous system development, while also indicating that this interaction is dispensable for vascular 
development.  Therefore, the severe vascular defects observed in mice lacking Npn-1 in endothelial cells 
(Tie-2 Cre; Npn-1fl/fl) together with the absence of vascular defects in mice selectively abolishing Sema3-
Npn1 binding (Npn1Sema-) suggest that it is most likely that VEGF-Npn-1 interaction that is responsible for 
the critical function of Npn-1 in developmental angiogenesis.  Mice carrying a mutation that specifically 
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abolishes VEGF binding without affecting Sema3 binding (Npn-1 VEGF-) will be needed to test this 
hypothesis. 
 
Although in vitro and in vivo studies over the past decades have furthered our understanding of the role of 
Nrp1 in angiogenesis, more questions have also been raised. So far there still remains several possible 
mechanisms underlying Nrp function in endothelial cells. One possibility is that the VEGF-Nrp1 interaction 
is critical for angiogenesis because it enhances VEGFR2 signaling.  Another hypothesis raised recently is 
that Npn1 aids in VEGFR2 recycling following VEGF stimulation. In heterologous cells expressing only 
VEGFR2, VEGF stimulation leads to the internalization of VEGFR2 into Rab7-positive vesicles that are 
destined for degradation [42]. However, in the presence of Nrp1, VEGF stimulation leads to internalization 
of the Nrp1/VEGFR2 complex into Rab11-positive vesicles, which are then recycled back to the cell surface. 
Whether this occurs in vivo is still awaiting examination. Finally, since Nrp1 has a large extracellular 
domain, it is formally possible that a ligand other than Sema3 and VEGF mediates its function in 
developmental angiogenesis. For example, when Nrp was initially identified as an adhesion molecule, it was 
suggested that a “ligand” may exist to mediate its function.  However, such ligand has not yet been 
identified.   
 
Plexins in developmental angiogenesis 
The function of plexins in developmental angiogenesis is relatively unknown in comparison to Semas and 
Nrps.  First, it is unclear whether plexins are actually expressed in endothelial cells, although several studies 
have suggested weak endothelial cell expression of PlexinA [14]. PlexinA1- PlexinA2-, PlexinA-3 and 
PlexinA4-null mice are all viable and fertile with no vascular abnormalities reported. Thus far, Plexin-D1 is 
the best characterized plexin that shown strong and broad endothelial cell expression and in vivo functional 
requirement for developmental angiogenesis.  Please see details above in the role of Sema3E section, and 




Semas control tumour progression 
Sema3s have a direct effect on cancer cells. The first evidence suggesting a potential role of Semas in 
controlling tumor angiogenesis derived from the identification of Sema3F as tumor suppressor in distinct 
deletion of 3p21.3 chromosomal region in lung cancer [44, 45]. Stemming from these data, several findings 
in recent years described Sema3s as modulators of cancer growth. For instance Sema3F inhibit cancer 
growth and metastasis formation in different xenograft mouse models [46]. In addition, it has been observed 
that the transcription repressor zinc finger E-box binding homeobox-box (ZEB)-1, highly up-regulated in 
lung cancer cells, inhibits the expression of Sema3F in these cells [47] and that, the up-regulation of Id2 in 
metastatic tumors over-expressing c-myc, inhibits Sema3F expression [48]. Other Sema3s, such as Sema3A, 
Sema 3B and Sema3F have anti-tumor effects. Indeed, Sema3A blocks breast cancer cell migration and 
invasion through an inhibitory autocrine mechanism involving its receptor Nrp-1 that modulates tumour cell 
motility [49, 50]. Moreover, the over-expression of Sema3A halts the migration and invasion in prostate 
cancer cells [51] and strongly impairs cell migration, invasion and suppress tumor growth and metastasis in 
melanoma cells [52]. Sema3B, similarly to Sema3F was identified as potential tumor suppressor. Sema3B is 
lost in lung cancer, and in neuroblastoma [53, 54] and can act directly on lung tumor cells by inhibiting 
anchorage-independent growth and inducing apoptosis [53]. 
Several reports described that Semas other than Sema3s regulate tumor progression. For instance Sema4D, a 
single pass transmembrane protein, binding  plexin-B1 receptor in tumor cells and by inducing the 
phosphorylation of Met and Ron, promotes tumor invasion and tumor metastasis [55, 56]. In addition, 
Sema4D induces tumor progression of head and neck squamous cell carcinomas [57]. Another example is 
Sema6D, a membrane-anchored semaphorin that use Plexin-A1 as its receptor. Interestingly, Sema6D, 
binding Plexin-A1 in complex with VEGFR-2, mediates survival and anchorage-independent growth of 
malignant mesothelioma cells [58]. Since both Plexin-A1 and VEGFR-2 are expressed on endothelial cells 
(ECs) it is possible that Sema6D could act also as a pro-angiogenic factor, but, this specific effect on the 






Semas regulate tumor angiogenesis 
A growing body of evidence so far implicate Semas as important modulators of both physiological and 
tumor angiogenesis [59-61]	   [62].  Several in vitro and in vivo studies demonstrate that Sema3s regulate 
angiogenesis. For instance Sema3A synergize with Sema3F to induce endothelial cell apoptosis [9] 
Interestingly, Sema3A and Sema3F, are expressed by ECs and may exert their effects in an autocrine 
fashion. Indeed, endogenous Sema3A controls, through autocrine loops, EC motility and vessel remodeling 
by inhibiting integrin function [63]. 
Sema3s controls tumor angiogenesis as well. In fact, it has been recently demonstrated, in different mouse 
models of spontaneous tumorigenesis, i.e. RIP-Tag2 neuroendocrine pancreatic tumour, K14-HPV16 skin 
carcinoma and HPV16/E2 uterine cervix carcinoma that Sema3A is an endogenous angiogenic inhibitor that 
is lost during tumor progression, when abnormal angiogenesis takes place. Notably, its re-expression in RIP-
Tag2 tumors by adeno-associated virus (AAV)-8 inhibits tumour growth, decreases vascular density, 
enhances pericyte coverage, and significantly enhances the survival of treated animals compared with 
controls [64]. Other studies, describing that systemic delivery of Sema3A in different mouse models of 
cancer impairs angiogenesis and metastasis formation [65], further highlights the anti-angiogenic and anti-
tumor effect of Sema3A. Re-expression of Sema3A in the tumors results in vessel normalization and in 
reduced tumor hypoxia. These findings further corroborate several evidence describing that the poorly 
functional tumor vasculature is due to an imbalance between pro- and anti-angiogenic factors as result of an 
overproduction of pro-angiogenic factors, such as VEGF [66] and a loss of angiogenic inhibitors such as 
Sema3A (and Sema3F) [64]. The restoration of this equilibrium in tumors induces a more functional and 
normalized vasculature [67]. It is well documented that tumor vessel normalization, a process occurring in 
response to the anti-angiogenic therapies that renders the tumor vasculature more efficient in delivering 
oxygen and drugs, represent a remarkably advantageous anti-cancer strategy, being also able to favor 
chemotherapy delivery and response to radiotherapy [66, 68, 69]. In this context, more recent data describe 
that Sema3A, by normalizing the vasculature, overcomes the resistance to the anti-angiogenic therapies. In 
fact, the simultaneous administration of Sema3A with the tyrosine kinase (TK) inhibitor Sunitinib or with the 
anti-VEGFR-2 antibody DC101, by increasing the normalization window and inhibiting tumor hypoxia, 
efficiently halts metastasis formation induced by these drugs in both RIP-Tag2 and HPV16/E2 mouse models 
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[70]. In addition, the administration of Sema3A as single agent or combined with Sunitinib in RIP-Tag2 
insulinoma, by improving vessel function, enhances the amount of doxorubicin delivered to the tumors. 
Interestingly, Sema3A-mediated reduction of tumor hypoxia, is able to lessen several hypoxia-induced 
pathways [70], such as hypoxia-inducible factor (HIF)-1α and NF-kB transcription factor, to inhibit Met TK 
receptor and to halt the epithelial-mesenchymal transition (EMT), shown to be highly involved in the 
promotion of a pro-invasive and metastatic phenotype [71, 72]. The underlying mechanisms regulating the 
pro-normalizing effects of Sema3s in cancer remain unclear. For instance, it remains to be elucidated how 
Sema3A (or other Sema3s) modulate the recruitment of resident or bone-marrow-derived perivascular cells 
to tumor vessels and which receptors, such as Nrps and PlexinAs expressed in both ECs and pericytes and 
their signaling pathways, are involved in this process.  
Another important Sema3, first described to have a potent direct anti-angiogenic activity, is Sema3F. In fact 
Sema3F blocks tumor angiogenesis and metastasis formation in mouse models of cancer [46, 73]. Very 
recently it has been shown that, similarly to Sema3A, Sema3F may act as an vascular normalizing agent. 
Indeed, it has been observed the down-modulation of Sema3F in Schwannomas in which the expression of 
the onco-suppressor merlin/ neurofibromatosis-2 is lost, releases the pro-angiogenic activity of VEGF-A, 
that, in turn, induces tumor vessel abnormalization [74]. Of note, re-expression of Sema3F in merlin/ 
neurofibromatosis-2 null cancer cells efficiently decreased tumor growth and normalizes the vasculature by 
reducing vessel area and permeability and by increasing pericyte vessel coverage [75]. Also Sema3E, 
similarly to Sema3A and Sema3F inhibits tumor angiogenesis. In fact Sema3E exert its anti-angiogenic 
effect through PlexinD1 in endothelial cells [76]. Differently from Sema3A and Sema3F, the furin-dependent 
proteolitic cleavage of Sema3E generates a 61 kDa isoform capable to enhance EC migration and promote 
metastatic spreading of breast cancer cells [77]. Moreover, by binding to PlexinD1, the 61 kDa Sema3E 
protein induces PlexinD1 association to the ErbB2 receptor and the consequent  activation the ErbB2/neu 
oncogenic kinase in tumor cells [78]. Notably, recent studies shows that a furin non-cleavable form of 
Sema3E that binds to PlexinD1 but does not induce the association with ErbB2, strongly inhibits 
angiogenesis and hampers metastatic spreading in different mouse models of cancer [79]. Other Sema3s, 
besides their direct tumor properties, display anti-angiogenic effects. For instance, studies demonstrate that 
Sema3B is an efficient angiogenic inhibitor in experimental angiogenesis, and that this inhibitory activity is 
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abrogated by furin-like pro-protein convertases [80]. More recently, a new role has been described for 
Sema3D in hampering tumor angiogenesis in glioblastoma tumor mouse model [81]. 
Probably, the most studied pro-angiogenic Sema is Sema4D. The soluble cleaved extracellular portion of 
Sema4D, promotes tumor angiogenesis by binding PlexinB1 [25, 57]. Interestingly, the binding of Sema4D 
to Plexin-B1, enhances Met phosphorylation inducing, in turn, tumor angiogenesis, invasion and metastasis 
dissemination [26]. Another potent pro-angiogenic Sema is Sema5A, a membrane-anchored Sema that, 
binding to PlxnB3, strongly enhance angiogenesis and metastasis formation in tumor pancreatic mouse 
models [82].  
 
Semas modulate the function of tumor-associated macrophages and fibroblasts 
A growing body of evidences described how tumour-associated inflammatory cells (e.g. macrophages and 
neutrophils) and cancer-associated fibroblasts (CAFs), represent key players in the regulation of cancer 
angiogenesis, invasion and metastatic dissemination [83, 84]. Studies have recently demonstrated that Semas 
and their receptors can regulate tumor angiogenesis and progression acting on these stroma cell types. 
 
Sema and inflammation in cancer 
Tumour angiogenesis is modulated by the recruitment of a series of bone marrow-derived cells (BMDCs) 
[83]. Among these cells, tumour-associated macrophages (TAMs) promote tumour angiogenesis [85] as well 
as the acquired resistance to anti-VEGF-A/VEGFR therapies [86]. Even though recent data demonstrate the 
presence in cancers of several subtypes of BMDCs with different and specific properties [83, 85], it 
conceivable to generalize that the shift of TAMs from an anti-tumor M1 polarization to a M2 alternatively 
activated phenotype induces tumor angiogenesis and support tumor progression [87].  
It is known that Semas regulate the immune system [88] and modulate the function of TAMs, contributing to 
the regulation of tumor angiogenesis. For instance, Sema3B, considered potential tumor suppressor and 
down-modulated in many cancers [53, 54], surprisingly, can promote metastasis formation by recruiting 
TAMs to the tumors. Indeed, Sema3B induces the production of IL-8 in cancer cells that contribute to the 
recruitment of TAMs that sustain tumor angiogenesis and progression [89]. Also Sema4A, a membrane-
anchored Sema that binds to plexinD1, has a dual effect on angiogenesis. Indeed, it has been shown that 
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Sema4A impairs physiological angiogenesis by acting directly on endothelial cells [90]. Recent studies 
demonstrate that Sema4A, binding Plexin-D1 expressed in macrophages, exerts a pro-angiogenic effect by 
enhancing VEGF-A production in these cells [91]. Notably, Sema4A is greatly expressed in macrophages 
activated by inflammatory stimuli and recruited at the injured area in a cardiac ischemia/reperfusion model 
[91], suggesting its potential role in regulating pathological angiogenesis. Interestingly, Sema7A, shown to 
promote experimental angiogenesis [92], also enhances the production of several pro-inflammatory 
molecules (e.g., IL-8, Il-6 and IL-1β) in macrophages and increases theirs migration [93]. Sema4D secreted 
by TAMs enhances tumor angiogenesis and contributes to the maturation of tumor blood vessels. 
Interestingly, a reduced recruitment to the tumors have been observed for TAMs derived from Sema4D 
knockout mice, compared with those derived from control animals [94].  
Recent findings show that certain Semas or Nrp-1 or other Sema receptors may define specific BMDC 
populations that can be recruited into cancers. For instance different Semas and their receptors (such as Nrp-
1, PlxnA1 and Sema6D) are specifically expressed by subsets of myeloid cells in cancers [95] and Nrps and 
PlxnAs are differently modulated in M2- compared to M1-polarized human macrophages [96]. It has been 
shown that changes in TAMs polarization can regulate tumor vessel normalization. In fact, recent data 
demonstrate that, in different mouse models of cancer, the histidine-rich glycoprotein (HRG) hampers cancer 
metastasis and normalizes the tumor vasculature by switching M2-like into M1-like phenotype. Notably, 
both Sema3A and VEGF-A are able to recruit a Nrp-1-expressing BMDCs that promote arterial maturation 
during physiological angiogenesis [97]. More recent studies shows that Sema3A recruits a specific subset of 
Nrp-1+, Cd11b+, Gr-1-, Tie-2- monocytes (NEM) in tumors mouse models of cancer capable to block cancer 
growth and to normalize the vasculature [98]. In addition, this specific NEM sub-population, can be purified 
from BM of normal mice and retains its anti-tumor and pro-normalizing effects when injected in tumor-
bearing mice [98]. Interestingly, while Sema3A exerts a chemoattractant effect on NEMs, it induces 
apoptosis in M2 human macrophages, known to express Nrp-1 [96]. These findings indicate that Semas and, 
in particular, Sema3s may differentially regulate macrophages depending on the expression of specific 
Sema3 receptors in myeloid populations present in cancers, and, consequently, regulate tumour angiogenesis.  
 
Sema and cancer-associated fibroblasts 
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Cancer-associated fibroblasts (CAFs) or myofibroblasts, derived from mesenchymal stem cells, BM-derived 
or local fibroblasts, promote tumor angiogenesis and cancer progression [83, 84, 99]. To date there are no 
direct experimental evidences describing effects of Semas on CAFs, but recent data suggest that Sema3 
receptors may have a role in their regulation in tumors. For instance, recent studies shows that Nrp-1 induces 
α5β1 integrin-mediated fibronectin fibril assembly, involved in regulation of matrix stiffness and tumor 
progression [100]. In addition Nrp-1, acting as TGF-β1 co-receptor, regulates the phosphorylation of Smad 
proteins and activate the fibroblasts promoting their conversion in myofibroblasts [101], described to support 
tumor growth and dissemination. Notably, it has been reported how leukocytes and CAFs can regulate each 
other and, together, contribute to cancer progression [83, 84]. In fact it has been shown that CAFs can 
regulate the activation of several immune cells and, by producing pro-inflammatory molecules, can recruit 
BMDCs able to promote tumor angiogenesis [102]. 
These data suggest therefore that Sema3s, their receptors and maybe other Semas may regulate the cross-talk 
between CAFs and inflammatory cells, and together, may contribute to the fine regulation of cancer 
microenvironment and tumor progression. 
 
Concluding remarks 
Work over the past decade has revealed increasingly important roles of semaphorins in vascular development 
and cancer, and has led to the identification of many new interactions between specific semaphorins and their 
receptors (Fig.1.). These unique ligand-receptor interactions regulate diverse aspects of vascular 
development and cancer progression, although we are still in the beginning stage of understanding these 
biological processes and their dynamic regulation. Many intriguing questions with respect to semaphorin 
signaling and function remain to be answered. For example, how are the different binding modes between 
semaphorins and receptor(s) (one ligand with multiple receptors or vice versa, forward or reverse signaling, 
trans or cis interactions) regulated? How are different ligand-receptor pairs assigned to different aspects of 
endothelial cell behavior, vessel sprouting and network formation?  One important future challenge is to 
understand precisely how semaphorin ligand binding translates into plexin activation and downstream 
signaling event in vivo.  Semas and their receptors are abnormally expressed during tumor progression both 
in cancer and stroma cells and their deregulated signal pathways my support or inhibit tumor growth and 
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angiogenesis. A growing body of evidences demonstrate that these versatile roles of Semas in tumors depend 
on the different Plexins and Nrps complexes present in different tumor types and on their interaction with 
receptor tyrosine kinases and integrins. For instance, current studies shows that the cleaved 61 kDa form of 
Sema3E, binding PlexinD1, induces the association to the ErbB2 receptor in tumor cells, [75] and that 
Sema4D binding Plexin-B1, induces Met activation [26] promoting, in both cases, metastatic spreading. In 
addition, recent data describes that Nrp-1 forms a complex with EGFR controlling its activation in tumors 
[103].	  These receptors complexes are differently expressed in tumor and stroma cells (i.e. ECs, pericytes, 
BMDCs and CAF) and can activate multiple signaling modules that can impair or promote cancer growth, 
angiogenesis, and metastasis dissemination. A better understanding of the global signaling partners and of 
the cross-talk between the multiple Semas signaling in the different cancer cell types will allow to better 










Fig.1.Schematic	  representation	  of	  specific	  interactions	  between	  semaphorins	  and	  their	  receptors	  
(neuropilins	  and	  plexins).	  Semaphorins	  can	  be	  categorized	  into	  eight	  distinct	  classes.	  Class	  1	  and	  2	  
semaphorins	  are	  found	  in	  invertebrates,	  whereas	  classes	  3-­‐7	  are	  expressed	  in	  vertebrates.	  The	  last	  class	  
of	  semaphorins	  includes	  those	  encoded	  by	  viruses.	  Class	  2	  and	  3	  semaphorins	  as	  well	  as	  viral	  
semaphorins	  are	  secreted.	  Class	  4,	  5	  and	  6	  semaphorins	  are	  transmembrane	  proteins	  and	  those	  in	  class	  
7	  are	  membrane-­‐anchored	  via	  glycophosphatidylinositol	  (GPI).	  All	  semaphorins	  consist	  of	  a	  large	  Sema	  
domain	  and	  PSI	  domain.	  Additional	  domains	  that	  are	  present	  in	  semaphorins	  include	  immunoglobulin	  
(Ig)-­‐	  like	  domains	  and	  thrombospondin	  repeats.	  Semaphorins	  signal	  through	  plexin	  receptors.	  Plexin	  A	  
and	  Plexin	  B	  are	  found	  in	  invertebrates.	  In	  contrast,	  vertebrates	  have	  four	  A-­‐type	  plexins,	  three	  B-­‐type	  
plexins,	  one	  C-­‐type	  plexins	  and	  one	  D-­‐type	  plexin.	  Plexins	  contain	  a	  Sema	  domain	  as	  well	  as	  PSI	  and	  IPT	  
domains.	  Moreover,	  the	  cytoplasmic	  domain	  of	  plexins	  contains	  two	  GAP	  domains,	  a	  GTP-­‐ase	  binding	  
domain	  and	  a	  PDZ	  domain	  (characteristic	  only	  for	  B-­‐type	  plexins).	  In	  invertebrates,	  Sema1s	  and	  Sema2s	  
signal	  through	  PlexinA	  and	  PlexinB,	  respectively.	  In	  vertebrates,	  Sema3s,	  Sema5s	  and	  Sema6s	  signal	  
through	  PlexinAs,	  with	  Sema3s	  also	  requiring	  neuropilins	  (Nrp1	  or	  Nrp2)	  to	  facilitate	  signaling.	  
Neuropilins	  are	  transmembrane	  receptors	  that	  are	  comprised	  of	  two	  complement-­‐like	  (CUB)	  domains,	  
two	  FV/FVIII	  coagulation	  factor-­‐like	  domains	  and	  a	  meprin-­‐like	  MAM	  domain	  and	  short	  cytoplasmic	  tail.	  
Sema3E	  can	  also	  bind	  directly	  to	  PlexinD1	  without	  neuropilins.	  Class	  4	  semaphorins	  interact	  with	  
PlexinBs	  while	  Sema4A	  can	  bind	  to	  PlexinD1.	  Sema3A	  has	  been	  suggested	  to	  bind	  to	  Nrp1/PlexinD1	  
complex.	  SEMA7A	  and	  viral	  semaphorins	  interact	  with	  PlexinC1.	  In	  addition,	  Semas	  and	  their	  receptors	  
can	  also	  modulate	  multiple	  signals	  in	  tumors	  by	  interacting	  with	  receptor	  tyrosine	  kinases	  and	  integrins	  
(not	  shown	  here	  due	  to	  the	  limitation	  of	  space).	  Semas,	  Nrps	  and	  Plexins	  are	  aberrantly	  expressed	  in	  
human	  cancer	  and	  tumor	  microenvironment	  cells.	  Different	  Semas	  and	  their	  receptors,	  can	  be	  
differently	  over-­‐expressed	  or	  down-­‐modulated	  or	  mutated,	  depending	  on	  the	  tumor	  types.	  Different	  
Semaphorins	  and	  their	  respective	  receptor(s)	  regulated	  different	  types	  and	  aspect	  of	  	  developmental	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